Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Akorn Inc. Collapsed Today

By Maxx Chatsko - Oct 1, 2018 at 10:52AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's official: A judge ruled that Fresenius can abandon the previously announced acquisition of Akorn.

What happened

Shares of Akorn (AKRX) fell more than 57% today after a judge ruled that Fresenius has the right to abandon a $4.75 billion merger agreement inked in early 2017 and rejected the generic drug manufacturer's argument that the agreement was set in stone.

The news isn't all that surprising. Fresenius announced in April 2018 that it was terminating the acquisition after uncovering evidence that the generic drug manufacturer had submitted fraudulent data to the U.S. Food and Drug Administration for multiple drugs over the years. The judge wrote that "the magnitude of inaccuracies would reasonably be expected to result in a material adverse effect," according to Reuters.

As of 11:34 a.m. EDT, the stock had settled to a 54.5% loss.

A declining stock chart on a touchscreen.

Image source: Getty Images.

So what

Today's news confirms what many investors and analysts had already feared to be true: that the acquisition was rightfully terminated and Akorn was going to have a long road ahead. The company's last hope was that a judge would rule that the merger agreement was final no matter what, but that was always a long shot. The generic drug manufacturer said it plans to appeal today's decision.

However, Mr. Market isn't putting much faith in that outcome shaking out favorably for Akorn, valuing the business at just $750 million -- roughly equivalent to book value at the end of June. Shares have now fallen more than 80% since the beginning of the year.

Now what

This is pretty straightforward for investors: Akorn has way too many red flags right now. The abandoned merger is bad news, the reason the agreement was terminated is even worse, and there are still many question marks surrounding the business. In the first half of 2018, revenue sank compared to the prior-year period and operating loss swelled to $116 million. It's possible for the business to rebuild, rebrand, and earn back the trust of shareholders and the broader market, but those efforts will take years and are likely to be expensive.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Akorn, Inc. Stock Quote
Akorn, Inc.
Fresenius Medical Care AG & Co. KGaA Stock Quote
Fresenius Medical Care AG & Co. KGaA
$18.97 (1.72%) $0.32

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.